CalciMedica Director Granted 40,000 Stock Options at $1.53-$1.65 Strike Price

CalciMedica Director Frederic Guerard received multiple stock option grants on June 24, 2025, following stockholder approval of the Amended 2023 Equity Incentive Plan.

Rhea-AI Filing Summary

CalciMedica Director Frederic Guerard received multiple stock option grants on June 24, 2025, following stockholder approval of the Amended 2023 Equity Incentive Plan. The grants include:

• 10,000 options at $1.53/share, vesting monthly over one year from March 26, 2025
• 5,000 immediately exercisable options at $1.53/share
• 15,000 options at $1.53/share, vesting monthly over one year from April 1, 2025
• 10,000 options at $1.65/share, vesting monthly over one year from June 24, 2025

All options expire in 2035, with the first three expiring on April 22 and the last on June 23. The final grant will fully vest by the 2026 annual stockholder meeting. Total grant value represents potential rights to purchase 40,000 shares of common stock. These grants were initially approved by the Board on April 23, 2025, contingent on stockholder approval.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 4 txns

Insider Guerard Frederic

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	10,000	$0.00	$0.00
Grant/Award	Director Stock Option (Right to Buy)	5,000	$0.00	$0.00
Grant/Award	Director Stock Option (Right to Buy)	15,000	$0.00	$0.00
Grant/Award	Director Stock Option (Right to Buy)	10,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 40,000 contracts (Direct)

Footnotes (5)

1. F1. The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.
2. F2. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.
3. F3. Immediately exercisable.
4. F4. 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.
5. F5. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did CALC director Frederic Guerard receive on June 24, 2025?

Frederic Guerard received a total of 40,000 stock options on June 24, 2025, broken down as follows: three grants of 10,000, 5,000, and 15,000 options at $1.53 per share, plus an additional grant of 10,000 options at $1.65 per share.

What is the exercise price of CALC's latest director stock options granted in June 2025?

The most recent director stock options granted on June 24, 2025, have two different exercise prices: $1.53 per share for three separate grants totaling 30,000 options, and $1.65 per share for one grant of 10,000 options.

When do CALC director Frederic Guerard's stock options expire?

The stock options granted at $1.53 per share expire on April 22, 2035, while the options granted at $1.65 per share expire on June 23, 2035.

What are the vesting terms for CALC's June 2025 director stock option grants?

The options have different vesting schedules: 10,000 shares vest monthly over one year from March 26, 2025; 5,000 shares are immediately exercisable; 15,000 shares vest monthly over one year from April 1, 2025; and 10,000 shares vest monthly over one year from June 24, 2025 (but will fully vest by the 2026 annual meeting).

Why were CALC's director stock options granted on June 24, 2025, but approved earlier?

The options were initially approved by CALC's Board of Directors on April 23, 2025, but were subject to stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan. The stockholders approved this amendment on June 24, 2025, enabling the official grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 06:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guerard Frederic

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD, #202

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$1.53	06/24/2025(1)		A		10,000		(2)	04/22/2035	Common Stock	10,000	$0	10,000	D
Director Stock Option (Right to Buy)	$1.53	06/24/2025(1)		A		5,000		(3)	04/22/2035	Common Stock	5,000	$0	5,000	D
Director Stock Option (Right to Buy)	$1.53	06/24/2025(1)		A		15,000		(4)	04/22/2035	Common Stock	15,000	$0	15,000	D
Director Stock Option (Right to Buy)	$1.65	06/24/2025		A		10,000		(5)	06/23/2035	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

2. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

3. Immediately exercisable.

4. 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

5. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders

	/s/ John Dunn, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.